Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 10/20 | 0.72 |
| ▸ | MEN1 | O00255 | 8/20 | 0.72 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.69 |
| ▸ | TSHR | P16473 | 2/20 | 0.69 |
| ▸ | HPGD | P15428 | 1/20 | 0.68 |
| ▸ | POLB | P06746 | 3/20 | 0.67 |
| ▸ | USP2 | O75604 | 1/20 | 0.65 |
| ▸ | CA12 | O43570 | 5/20 | 0.62 |
| ▸ | CA9 | Q16790 | 5/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15836637 | 0.81 | KMT2A (1.00) | KMT2AMEN1KDM4EALDH1A1TSHR | |
| SCHEMBL15836702 | 0.81 | KMT2A (0.79) | KMT2AMEN1KDM4EALDH1A1TSHR | |
| SCHEMBL15836707 | 0.78 | USP2 (0.71) | KMT2AMEN1KDM4EALDH1A1TSHR | |
| SCHEMBL12473143 | 0.78 | USP2 (0.74) | KMT2AMEN1KDM4EALDH1A1TSHR | |
| SCHEMBL466909 | 0.78 | CA12 (0.83) | KMT2AMEN1KDM4EALDH1A1HPGD | |
| SCHEMBL15836633 | 0.78 | TSHR (0.74) | KMT2AMEN1KDM4EALDH1A1TSHR | |
| SCHEMBL15836709 | 0.77 | ALDH1A1 (0.73) | KMT2AMEN1ALDH1A1USP2CA12 | |
| SCHEMBL20588779 | 0.74 | MCL1 (0.61) | KMT2AMEN1KDM4EALDH1A1TSHR | |
| SCHEMBL15836705 | 0.74 | MEN1 (0.72) | KMT2AMEN1KDM4EALDH1A1TSHR | |
| SCHEMBL2316901 | 0.73 | CYP2D6 (0.82) | KMT2AMEN1KDM4EALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140179681-A1 | METHODS AND COMPOSITIONS OF TARGETED DRUG DEVELOPMENT | Errico, Joseph P. (US) | 2014-06-26 | — | — | US | disclosed |
| US-20140179681-A1 | METHODS AND COMPOSITIONS OF TARGETED DRUG DEVELOPMENT | Errico, Joseph P. (US) | 2014-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140179681-A1 | METHODS AND COMPOSITIONS OF TARGETED DRUG DEVELOPMENT | EGFR, ERBB2, ERBB3 | KMT2A 3667/4885MEN1 3121/4885KDM4E 3370/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.